

Studies	Characteristics	Outcomes reported: n/N				Adjustment for covariates	N-O Scale*
		A	AB	B	O		
Li <i>et al.</i> (2)	N=265 Retrospective cohort study, China	Mortality				ND	8/9
		20/104	8/26	15/67	14/68		
Zhao <i>et al.</i> (3)	N=1775 Retrospective cohort study, China	Mortality				ND	8/9
		85/670	19/178	50/469	52/458		
Goker <i>et al.</i> (4)	N= 186 Retrospective cohort study, Turkey	Intubation				ND	7/9
		7/106	1/14	0/20	3/46		
Wu <i>et al.</i> (9)	N=187 Retrospective case control study, China	Dyspnea				ND	5/9
		29/69	7/14	10/63	13/41		
Latz <i>et al.</i> (10)	N=1289 Retrospective cohort study, USA	Intubation				Adjusted for sex, race, primary language, aspirin use, comorbidities	6/9
		38/440	6/61	15/201	49/587		
Dzik <i>et al.</i> (11)	N=957 Retrospective cohort study, USA	Mortality				ND	7/9
		45/311	8/41	17/140	65/465		
Ray <i>et al.</i> (16)	N=225556 Retrospective cohort study, Canada	Severe disease or mortality				Adjusted for age, sex, area-level income quintile, rurality, and local health integration network, history of cardiac ischemia or arrhythmia, cancer, CKD, CHF, DM	8/9
		474/81797	75/10221	242/33536	537/100002		
Yaylacı <i>et al.</i> (18)	N=397 Descriptive cross-sectional study, Turkey	Mortality				ND	6/9
		15/201	1/21	5/55	8/120		
Zietz <i>et al.</i> (19)		Intubation or Mortality				Adjusted for race and ethnicity	8/9
		215/786	32/94	124/392	359/1122		

**Supplementary Table 1:** Summarizing the characteristics of the studies included in the present meta-analysis.

\*Newcastle-Ottawa quality assessment scale for cohort studies. Score >6 was taken as good quality and 5-6 as moderate quality. Clinical outcomes data in respective blood groups reported as n/N.

ND: not done, OR: odds ratio, CKD: Chronic kidney disease, CHF: Congestive heart failure, DM: Diabetes mellitus,